After trial failure upon trial failure in Alzheimer's disease will big pharma be prepared to fund a trial using a new approach instead of the amyloid-targeting drugs, that have caused so mu
While at Reuters Pharma Europe in Barcelona the other week, pharmaphorum web editor Nicole Raleigh spoke with Florian Schnappauf, VP of enterprise commercial strategy at Veeva Europe, about
It’s 2024, and in most clinical trials, data is still being moved from the EHR to the EDC manually – with employees reading data from one screen and typing it onto another.